4,918 reports of this reaction
1.6% of all RIVAROXABAN reports
#19 most reported adverse reaction
THROMBOSIS is the #19 most commonly reported adverse reaction for RIVAROXABAN, manufactured by Janssen Pharmaceuticals, Inc.. There are 4,918 FDA adverse event reports linking RIVAROXABAN to THROMBOSIS. This represents approximately 1.6% of all 299,230 adverse event reports for this drug.
RIVAROXABAN has an overall safety score of 88 out of 100. Patients taking RIVAROXABAN who experience thrombosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THROMBOSIS is a less commonly reported adverse event for RIVAROXABAN, but still significant enough to appear in the safety profile.
In addition to thrombosis, the following adverse reactions have been reported for RIVAROXABAN:
The following drugs have also been linked to thrombosis in FDA adverse event reports:
THROMBOSIS has been reported as an adverse event in 4,918 FDA reports for RIVAROXABAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
THROMBOSIS accounts for approximately 1.6% of all adverse event reports for RIVAROXABAN, making it a notable side effect.
If you experience thrombosis while taking RIVAROXABAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.